Cantourage Group SE Broadens Cannabis Portfolio with New Ingredients

Cantourage Group SE, a prominent European medical cannabis company, is diversifying its product range with new cannabis active ingredients. These include a crude extract and a distillate based on the popular "Blue Dream" strain. The aim is to empower pharmacies in preparing patient-specific compounded medicines, including vapes and edibles, subject to legal standards.

This initiative enhances Cantourage's existing offerings, which mainly consisted of cannabis flowers and extracts. By providing standardized cannabis materials, Cantourage facilitates pharmacies in creating customized formulations, responding to specific patient needs in cannabinoid therapies.

The company's focus on individualized cannabis preparations targets a self-pay market segment, potentially increasing accessibility beyond Germany’s statutory health insurance constraints. These new ingredients will debut at expopharm in Munich, showcasing Cantourage's commitment to innovative pharmaceutical applications.